Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis Healthcare Bid...

    Fortis Healthcare Bid Likely to open again

    Written by Ruby Khatun Khatun Published On 2018-05-28T16:25:27+05:30  |  Updated On 28 May 2018 4:25 PM IST
    Fortis Healthcare Bid Likely to open again

    New Delhi: The bid for Fortis healthcare is likely to open again as the victorious bidders have given their nod to re-open the bidding process. In May, the board of Fortis Healthcare recommended the binding offer of the Munjal-Burmans combine to the shareholders after 18 months of hectic parleys with several potential investors for the sale of its business.


    Read also: Battle For Fortis: Munjal-Burmans emerge Victorious


    Fortis Healthcare on Monday said the Munjals-Burmans combine, whose bid for investing Rs 1,800 crore was approved by its board, have consented to re-opening the bidding process.


    In a regulatory filing, Fortis Healthcare said it has received a letter from Hero Enterprise Investment Office and Burman family Office...giving their consent to re-open the bidding process to enable the company to move ahead with the fund-raising transaction.

    In a letter to the board of directors, Munjals-Burmans combine expressed "deep anguish and regret" and said "it appears that there may be indecision on the part of the company regarding the bid process, which we understand could be on account of a few shareholders indicating their preference to the company for re-open of the bid process".

    Fortis Healthcare, however, did not clarify whether it will re-open the bidding process.

    When contacted, a Fortis spokesperson said the company's board will take a decision on whether the bidding should be re-opened or not, without specifying when the meeting would take place.

    "Necessary intimation to the regulator and stock exchanges would be given accordingly," he said.

    Fortis' board of directors is scheduled to meet on May 30 to consider and approve the audited financial results for the quarter and financial year ended March 31, 2018.


    Last week, Fortis board was reconstituted after its shareholders had voted out its director, Brian Tempest, from the board in the extraordinary general meeting (EGM) held on May 22.


    Earlier, out of four directors whose removals were sought by two institutional investors, three directors - Harpal Singh, Sabina Vaisoha and Tejinder Singh Shergill - had resigned ahead of an EGM called to vote on the matter.


    The resignations of three directors and removal of Tempest has cast a shadow over the ongoing attempt to sell Fortis as these four directors were among the five who had voted in favour of Munjals-Burmans combine's Rs 1,800-crore bid for the healthcare firm.

    bid processbidding processBurman Family OfficeconsentEGMextraordinary general meetingFortisFortis HealthcareHero Enterprise Investment OfficeMunjals-Burmans combinere-open
    Source : with PTI inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok